Analysts Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $34.40

enGene Holdings Inc. (NASDAQ:ENGN) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the last year is $34.40.

A number of research firms recently issued reports on ENGN. UBS Group began coverage on enGene in a research note on Thursday, March 28th. They set a “buy” rating and a $37.00 target price for the company. Leerink Partnrs reissued an “outperform” rating on shares of enGene in a research note on Tuesday, February 20th. Wells Fargo & Company started coverage on enGene in a research report on Monday, April 22nd. They set an “overweight” rating and a $30.00 price target for the company. Guggenheim started coverage on enGene in a research report on Monday, April 15th. They set a “buy” rating and a $34.00 price target for the company. Finally, Morgan Stanley started coverage on enGene in a research report on Friday, March 8th. They set an “overweight” rating and a $40.00 price target for the company.

enGene Stock Performance

enGene stock opened at $15.50 on Monday. enGene has a 1 year low of $6.69 and a 1 year high of $43.00. The company’s 50-day simple moving average is $16.20.

Insider Buying and Selling at enGene

In other news, major shareholder De Solidarite Des Travai Fonds sold 4,575 shares of enGene stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $15.01, for a total transaction of $68,670.75. Following the sale, the insider now directly owns 3,084,107 shares of the company’s stock, valued at $46,292,446.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Institutional Investors Weigh In On enGene

A number of hedge funds have recently added to or reduced their stakes in the business. Vivo Capital LLC bought a new stake in shares of enGene during the fourth quarter valued at approximately $6,264,000. Omega Fund Management LLC bought a new stake in shares of enGene during the fourth quarter valued at approximately $10,441,000. BVF Inc. IL bought a new stake in shares of enGene during the fourth quarter valued at approximately $20,777,000. Finally, Fcpm Iii Services B.V. bought a new stake in shares of enGene during the fourth quarter valued at approximately $80,097,000. 64.16% of the stock is currently owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.